Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,...
Reexamination Certificate
2006-06-15
2009-10-13
Canella, Karen A (Department: 1643)
Drug, bio-affecting and body treating compositions
Conjugate or complex of monoclonal or polyclonal antibody,...
C424S179100, C424S181100, C424S182100, C424S183100, C514S279000, C514S449000
Reexamination Certificate
active
07601354
ABSTRACT:
The present invention is based on the discovery that the administration of at least one immunoconjugate and at least one chemotherapeutic agent provides an unexpectedly superior treatment for cancer. The present invention is directed to compositions comprising at least one immunoconjugate and at least one chemotherapeutic agent and to methods of treating cancer using at least one immunoconjugate and at least one chemotherapeutic agent. The present invention also provides methods of modulating the growth of selected cell populations, such as cancer cells, by administering a therapeutically effective amount of at least one chemotherapeutic agent and at least one immunoconjugate.
REFERENCES:
patent: 5208020 (1993-05-01), Chari et al.
patent: 5242824 (1993-09-01), Hellstrom et al.
patent: 5416064 (1995-05-01), Chari et al.
patent: 5679648 (1997-10-01), McCaffrey et al.
patent: 6340701 (2002-01-01), Chari et al.
patent: 58-167592 (1983-10-01), None
patent: 62-195387 (1987-08-01), None
patent: 2002-541088 (2002-12-01), None
patent: 2002-543093 (2002-12-01), None
patent: 2003-503365 (2003-01-01), None
patent: WO 98/08506 (1998-03-01), None
patent: WO 03/070234 (2003-08-01), None
Drug Facts and Comparisons, 1999, p. 3283, Cada et al, Ed.s.
Chari, Accounts of Chemical Research, Jan. 2008, vol. 41, pp. 98-106.
Sierra and de la Torre, Angewandte Chemie, 2000, vol. 39, pp. 1538-155.
Clark (Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, 1993, pp. 4-5).
Blattler et al, ‘Immunoconjugates’, In: Cancer Therapeutics: Experimental and Clinical Agents, B. Telcher, Ed., 1997, pp. 371- 394).
McSharry, Clinical Microbiology Reviews, 1994, vol. 7, pp. 576-604.
Malaga et al, Infection and Immunity, 2001, vol. 69, pp. 353-359.
Roman et al, Acta Virologica, 1991, vol. 35, pp. 503-510.
Ertenli et al, The Journal of Rheumatology, 1998, vol. 25, pp. 1054-1058.
Wilson et al, The Journal of Rheumatology, 1993, vol. 20, pp. 1282-1287.
Kalman et al, Autoimmunity, 2002, vol. 35, pp. 225-234.
Novota et al, Transplantation, 2008, vol. 85, pp. 1809-1816.
Fitzpatrick and Wheeler, International Immunopharmacology, 2003, vol. 3, pp. 1699-1714.
Fedier et al., Annals of Oncology, 2003, vol. 14, pp. 938-945.
Gupta, Radley, S., “Cross-Resistance of Vinblastine and Taxol-Resistant Mutants of Chinese Hamster Ovary Cells to Other Anticancer Drugs”, Cancer Treatment Reports, vol. 69, No. 5, pp. 515-172, May 5, 1998.
Liu, Changnian and Ravi V.J. Chari, “The Development of Antibody Delivery Systems to Target Cancer with Highly Potent Maytansinoids”, Exp. Opin. Invest. Drugs, vol. 6, No. 2, pp. 169-172, Feb. 1997.
Nakajima, Osamu, Yasuko Sugishita, Yuichi Hashimoto and Shigeo Iwasaki, “Increase in the Chemically-Induced Differentiation of Human Leukemia Cells Lines by Tubulin Disruptors”, Biol. Pharm. Bull, vol. 17, No. 5, pp. 742-744, 1994.
Liu C., et al., “Cure of Large Human Colon Cancer Xenografts by a C242-Maytansinoid Conjugate”, Proceedings of the Annual Meeting of the American Association for Cancer Research, vol. 37, No. 2, pp. 466-467, Apr. 20, 1996.
Jordan, Allan, John A. Hadfield, Nicholas J. Lawrence and Alan T. McGown, “Tubulin as a Target for Anticancer Drugs: Agents Which Interact with the Mitotic Spindle”, Medicinal Research Reviews, vol. 18, No. 4, pp. 259-296, 1998.
Jul. 12, 2004. Supplementary Partial European Search Report from European Patent Application No. 00970516.1.
Lynch et al, Journal of Clinical Oncology, 1997, vol. 15, pp. 723-734), Abstract.
Schlom, Monoclonal Antibodies: They're More and Less Than You Think, IN: Molecular Foundations of Oncology, 1991, Ed. S. Broder pp. 95-134.
Chari et al, Cancer Research, 1992, vol. 52, pp. 127-131.
Siegall et al, Proc Annual Meeting Assoc Cancer Research, 1997, vol. 38, p. A185.
Iwasaki et al, Yakugaku Zasshi, 1998, vol. 118,, pp. 111-126), Abstract.
Pegram et al , Oncogene, 1999, vol. 18, pp. 2241-2251.
Watson et al, Proc Ammu Meet Am Assoc Cance Res, 1996, vol. 37, p. A2997.
Guchelaar et al, Clinical Oncology, 1994, vol. 6, pp. 40-48, Abstract.
Liu et al, Proc Annu Meeting Am Assoc Cancer Research, 1997, vol. 38, p. A190.
Lidor et al, Journal of Clinical Investigation, 1993, vol. 92, pp. 2440-2447.
Rosenblum et al, Cancer Immunol Immunother, 1996, vol. 42, pp. 115-121.
Fiorentino et al, Dev Oncol, 1988, vol. 54, pp. 415-435, Abstract.
ImmunoGen, Inc. Press Release (Feb. 25, 1999).
Apelgren et al, Cancer Research, 50:3540-3544 (1990).
Bai, et al, Cancer Research, 56:4398-4406 (1996).
Dieras et al, 10thNCI-EORTC Symposium on New Drugs In Cancer Therapy, p. 100, Abstract Nos. 382 and 383 (Jun. 1998).
Glisson, et al., Journal of Clinical Oncology, 17(8):2309-2315 (Aug. 1999).
Griffin, et al., The Journal of Immunology, 130(6): 2947-2951 (1983).
Kibbelaar et al., Journal of Pathology, 159:23-28 (1989).
Laguzza et al., J. Med. Chem., 32: 548-555(1989).
Liu et al, Proceedings of the American Association for Cancer Research, 38:29 Abstract No. 190 (1997).
Liu et al, Proc natl. Acad. Sci. USA, 93:8618-8623 (1996).
Morris et al., Journal of Clinical Oncology, 16(3):1094-1098 (Mar. 1998).
Panda et al., Proc. Natl. Acad. Sci. USA, 95:9313-9318 (Aug. 1998).
Pitot et al, Clinical Cancer Research, 5:525-531 (Mar. 1999).
Pettit et al, J. Am Chem. Soc., 111:5463-5465 (1989).
Roguska et al., Protein Engineering, 9(10):895-904 (1996).
Roguska et al., Proc. Natl. Acad. Sci. USA, 91:969-973 (1994).
Rygaard et al, Br. J. Cancer, 65;573-577 (1992).
Schrappe et al, Cancer Research, 52:3838-3844 (1992).
Smith, et al, Cancer Research, 54:3779-3784 (1994).
Villalona-Calero, journal of Clinical Oncology, 16(8):2770-2779 (Aug. 1998).
Doria et al., Cancer 62:1939-1945 (1988).
Liu et al, Proc. Natl. Acad. Sci. USA, 93:8618-8623 (Aug. 1996).
Embleton et al., Br. J. Cancer, 47:043-049 (1993).
Mendelsohn et al., Clin. Cancer Res., 3:2703-2707 (Dec. 1997).
Ghaemmaghami et al, Chest, 113 (Supp. 1): 86S 91s (Jan. 1998).
Christian et al., Gynecologic Oncology, 55:s143-s150 (1994).
Stern et al., Cancer Vaccines and Immunotherapy, pp. 1-18 and 195-206, Cambridge University Press (2000).
Kast, Peptide-Based Cancer Vaccines, pp. 1-16, Eurekah.com (2000).
“Monoclonal Anti-body Production,” A report of the Committee on Methods of Producing Monoclonal Antibodies, Institute for Laboratory Animal Research, National Research Council, National Academy Press, Washington DC 1999.
Friedman et al., Cancer Research, 53(2):334-339 (1993).
Webster's New Collegiate Dictionary, G&C Merriam Co., p. 1174 (1981).
Pastan, et al., J. Biol. Chem. 264:15157-15160 (1989).
Kupchan et al., J. Am. Chemical Society, 94: 1354-1356 (1972).
Sandvig et al, The EMBO Journal, 19:5943-5950 (2000).
Lambert, et al., Cancer Research, 51 (23 Pt 1):6236-6242 (1991) (Abstract).
Canella Karen A
Immunogen Inc.
Sughrue & Mion, PLLC
LandOfFree
Compositions and methods for treating cancer using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treating cancer using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treating cancer using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4078027